Attractive Stocks Alert: MannKind (NASDAQ: MNKD), Gilead Sciences, Inc …iStreetWireElotuzumab, for instance, is associated with Bristol-Myers Squibb (BMY), while Daclizumab is being developed with Biogen Idec. AbbVie Inc (NYSE:ABBV) ranged in price b…
Barron’s (blog)AbbVie: No Upside For Hep-C, Little Upside For Stock, Morgan Stanley SaysBarron’s (blog)Elotuzumab, for instance, is partnered with Bristol-Myers Squibb (BMY), while Daclizumab is being developed with Biogen Idex (BIIB). Shares of AbbVie…
|
Los fármacos que vienen para la esclerosis múltiple
El Correo Daclizumab es otro de los anticuerpos monoclonales que se administra cada cuatro semanas, vía subcutánea. Hasta ahora sus resultados en ensayos clínicos (SELECT, DECIDE) “han sido francamente buenos”. Por otra parte, el medicamento ocrelizumab … |
|
Los fármacos que vienen para la esclerosis múltiple
El Diario Montanes Daclizumab es otro de los anticuerpos monoclonales que se administra cada cuatro semanas, vía subcutánea. Hasta ahora sus resultados en ensayos clínicos (SELECT, DECIDE) “han sido francamente buenos”. Por otra parte, el medicamento ocrelizumab … |
|
Neue Hoffnung Entwicklungsschub bei MS-Arzneien
Ärzte Zeitung Daclizumab blockiert Interleukin 2, indem es an den Rezeptor CD25 bindet. Der Antikörper wurde lange zur Immunsuppression in der Transplantationsmedizin verwendet und wird jetzt zur Therapie bei Patienten mit schubförmiger Multipler Sklerose geprüft. |
Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research – Zacks …NASDAQThe company has collaborations with companies like Roche (Rituxan), Acorda (Fampyra), Biovitrum (Eloctate and Alprolix) and AbbVie (daclizumab) among others. In ter…
Medical Marketing and Media |
Analyst: Don’t underestimate AbbVie
Medical Marketing and Media Rubin pointed out that the MS drug daclizumab, which is being developed with Biogen Idec, has safety and tolerability issues that undercut its efficacy profile. Rubin said heat surrounding new oral agents “with less safety concerns,” limit the … |
ASH 2013 Preview: Novel Immunotherapies Under Development For The …The Myeloma Beacon… then had their regulatory T cells removed via treatment of the patients with an antibody called Simulect (basiliximab), and three patients underwent transplantat…
Biogen Idec Inc (BIIB): Biogen Idec 5-Year Revenue OutlookSeeking AlphaIn its drug pipeline, the company is conducting phase 3 trials on Daclizumab (ant-CD25) for multiple sclerosis. The phase 3 data are expected mid-2014. Biogen is also conducting sev…
|
ECTRIMS 2013 – Neues zu Forschung und Therapie für Multiple Sklerose
DMSG Multiple Sklerose Nachrichten Dieses traf u.a. zu auf Alemtuzumab, Peginterferon beta-1a, Laquinimod, Ocrelizumab und Daclizumab. Neuroprotektion (Schutz der Nervenzellen) Das Thema Neuroprotektion spielte eine große Rolle auf dem Kongress. Einer von vielen Ansätzen dazu ist … |